Active Ingredient History
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5). Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alcohol Drinking (Phase 2)
Alcohol-Induced Disorders (Phase 2)
Alcoholism (Early Phase 1)
Anti-Dyskinesia Agents (Phase 2)
Chorea (Phase 2)
Cigarette Smoking (Phase 1)
Cocaine-Related Disorders (Phase 2)
Dermatology (Phase 2)
Drugs, Investigational (Phase 2)
Dyskinesia, Drug-Induced (Phase 2)
Dyskinesias (Phase 2)
Fragile X Syndrome (Phase 2/Phase 3)
Gastroesophageal Reflux (Phase 1)
Huntington Disease (Phase 2)
Kidney Diseases (Phase 1)
Levodopa (Phase 2)
Liver Diseases (Phase 1)
Movement Disorders (Phase 2)
Obsessive Behavior (Phase 2)
Parkinson Disease (Phase 2)
Parkinsonian Disorders (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue